SI1587542T1 - Uporaba anti-cd100 protiteles - Google Patents
Uporaba anti-cd100 protitelesInfo
- Publication number
- SI1587542T1 SI1587542T1 SI200431917T SI200431917T SI1587542T1 SI 1587542 T1 SI1587542 T1 SI 1587542T1 SI 200431917 T SI200431917 T SI 200431917T SI 200431917 T SI200431917 T SI 200431917T SI 1587542 T1 SI1587542 T1 SI 1587542T1
- Authority
- SI
- Slovenia
- Prior art keywords
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03290247A EP1442749A1 (en) | 2003-01-31 | 2003-01-31 | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| PCT/EP2004/001743 WO2004067034A1 (en) | 2003-01-31 | 2004-02-02 | Use of anti-cd100 antibodies |
| EP04707230A EP1587542B1 (en) | 2003-01-31 | 2004-02-02 | Use of anti-cd100 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1587542T1 true SI1587542T1 (sl) | 2012-10-30 |
Family
ID=32605433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200431917T SI1587542T1 (sl) | 2003-01-31 | 2004-02-02 | Uporaba anti-cd100 protiteles |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8067247B2 (sl) |
| EP (2) | EP1442749A1 (sl) |
| JP (1) | JP4768597B2 (sl) |
| BR (1) | BRPI0406689A (sl) |
| CA (1) | CA2514226C (sl) |
| CY (1) | CY1112953T1 (sl) |
| DK (1) | DK1587542T3 (sl) |
| ES (1) | ES2388735T3 (sl) |
| PT (1) | PT1587542E (sl) |
| SI (1) | SI1587542T1 (sl) |
| WO (1) | WO2004067034A1 (sl) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576754B2 (en) * | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| EP1442749A1 (en) * | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| WO2008100995A1 (en) * | 2007-02-14 | 2008-08-21 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
| SG175417A1 (en) | 2009-05-08 | 2011-12-29 | Vaccinex Inc | Anti-cd100 antibodies and methods for using the same |
| EP2487242A1 (en) * | 2011-02-09 | 2012-08-15 | Ruprecht-Karls-Universität Heidelberg | B-type plexin antagonists and uses thereof |
| PT2711023T (pt) | 2011-05-13 | 2017-10-02 | Univ Nat Corp Tokyo Medical & Dental | Promotor da osteogénese |
| EA029023B1 (ru) * | 2011-10-11 | 2018-01-31 | Вэксинекс, Инк. | Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) * | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| CA3098741A1 (en) * | 2013-06-25 | 2014-12-31 | Vaccinex, Inc. | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) * | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| EP3241844B1 (en) | 2014-12-03 | 2021-04-21 | Aimed Bio Inc. | Antibody against neuropilin 1 and use thereof |
| JP7072521B2 (ja) | 2016-04-22 | 2022-05-20 | バクシネックス インコーポレーティッド | ポックスウイルス細胞外エンベロープビリオン上での膜内在性タンパク質の提示 |
| AU2017273170B2 (en) * | 2016-06-03 | 2020-08-27 | Aimed Bio Inc. | Anti-NRP1 antibody screening method |
| RU2747557C2 (ru) | 2016-08-02 | 2021-05-06 | Вэксинекс, Инк. | Улучшенные способы получения библиотек полинуклеотидов в вирусах осповакцины/эукариотических клетках |
| CN110446504B (zh) | 2017-03-20 | 2024-07-26 | 瓦西尼斯公司 | 用脑信号蛋白-4d抗体联合表观遗传调节剂治疗癌症 |
| CA3061963A1 (en) | 2017-05-05 | 2018-11-08 | Vaccinex, Inc. | Human anti-semaphorin 4d antibody |
| BR112021000949A2 (pt) * | 2018-07-19 | 2021-04-27 | The University Of Tokyo | agente terapêutico ou profilático para mielopatia associada a htlv-1 (ham) e método para tratar ham |
| CN113631230A (zh) | 2019-03-28 | 2021-11-09 | 瓦西尼斯公司 | 用于癌症治疗的脑信号蛋白-4d拮抗剂 |
| WO2021021991A1 (en) | 2019-08-01 | 2021-02-04 | Vaccinex,Inc. | Combined inhibition of semaphorin-4d and tgfb and compositions therefor |
| MX2022016188A (es) | 2020-06-25 | 2023-10-30 | Vaccinex Inc | Uso de moléculas de unión a semaforina-4d para el tratamiento del síndrome de rett. |
| KR20240063995A (ko) | 2021-09-27 | 2024-05-10 | 백시넥스 인코포레이티드 | 신경퇴행성 장애를 치료하기 위한 항-세마포린-4d 결합 분자의 사용을 위한 예측 결과 프로파일링 |
| US20230331863A1 (en) | 2022-02-13 | 2023-10-19 | Vaccinex, Inc. | Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease |
| CN117866091A (zh) * | 2022-10-12 | 2024-04-12 | 三优生物医药(上海)有限公司 | 抗cd100抗体及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686087A1 (fr) * | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US6576754B2 (en) * | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| US6635742B1 (en) * | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
| EP1442749A1 (en) * | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
-
2003
- 2003-01-31 EP EP03290247A patent/EP1442749A1/en not_active Withdrawn
-
2004
- 2004-02-02 PT PT04707230T patent/PT1587542E/pt unknown
- 2004-02-02 CA CA2514226A patent/CA2514226C/en not_active Expired - Fee Related
- 2004-02-02 BR BR0406689-8A patent/BRPI0406689A/pt not_active Application Discontinuation
- 2004-02-02 ES ES04707230T patent/ES2388735T3/es not_active Expired - Lifetime
- 2004-02-02 EP EP04707230A patent/EP1587542B1/en not_active Expired - Lifetime
- 2004-02-02 JP JP2006501920A patent/JP4768597B2/ja not_active Expired - Fee Related
- 2004-02-02 US US10/544,031 patent/US8067247B2/en not_active Expired - Fee Related
- 2004-02-02 SI SI200431917T patent/SI1587542T1/sl unknown
- 2004-02-02 DK DK04707230.1T patent/DK1587542T3/da active
- 2004-02-02 WO PCT/EP2004/001743 patent/WO2004067034A1/en active Application Filing
-
2011
- 2011-10-11 US US13/270,449 patent/US20120027758A1/en not_active Abandoned
-
2012
- 2012-08-07 CY CY20121100707T patent/CY1112953T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1587542T3 (da) | 2012-07-30 |
| CY1112953T1 (el) | 2016-04-13 |
| CA2514226A1 (en) | 2004-08-12 |
| US20060233793A1 (en) | 2006-10-19 |
| ES2388735T3 (es) | 2012-10-18 |
| WO2004067034A1 (en) | 2004-08-12 |
| JP2006516594A (ja) | 2006-07-06 |
| BRPI0406689A (pt) | 2005-12-20 |
| CA2514226C (en) | 2015-04-28 |
| EP1587542A1 (en) | 2005-10-26 |
| EP1442749A1 (en) | 2004-08-04 |
| EP1587542B1 (en) | 2012-06-13 |
| US20120027758A1 (en) | 2012-02-02 |
| JP4768597B2 (ja) | 2011-09-07 |
| US8067247B2 (en) | 2011-11-29 |
| PT1587542E (pt) | 2012-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1587542T1 (sl) | Uporaba anti-cd100 protiteles | |
| IL175935A0 (en) | Solid forms of anti-egfr antibodies | |
| EP1616881A4 (en) | ANTI-MPL ANTIBODIES | |
| IL175608A0 (en) | Antibodies | |
| PT1599504E (pt) | Anticorpo modificado | |
| GB0325192D0 (en) | Method of use | |
| EP1494693A4 (en) | SPECIFIC ANTIBODIES TO CRIPTO | |
| ZA200604074B (en) | Anti-IGFR1 antibody therapeutic combinations | |
| IL173273A0 (en) | Modified human igf-1r antibodies | |
| AU158373S (en) | Set of containers | |
| PL375405A1 (en) | Antibodies | |
| IL173557A0 (en) | Variable antibodies | |
| EP1745573A4 (en) | PROCESS FOR PREPARING 2-DEOXY-BETA-L-NUCLEOSIDES | |
| GB0324147D0 (en) | Functionilisation of particles | |
| IL172510A0 (en) | Antibodies and uses thereof | |
| GB2404736B (en) | Determination of geophone coupling | |
| IL172511A0 (en) | Specific human antibodies | |
| GB0306618D0 (en) | Antibody | |
| GB0226878D0 (en) | Antibodies | |
| PL377902A1 (pl) | Nowe zastosowanie kompleksu fosfor-azot-metal | |
| SI2301576T1 (sl) | Terapevtska uporaba protiteles proti CS1 | |
| GB2399559B (en) | Construction of container | |
| GB0329711D0 (en) | Antibodies | |
| GB0317974D0 (en) | Novel antibodies | |
| GB0327195D0 (en) | Novel use |